September 12, 2018 / 6:53 AM / 7 months ago

Teva to hold Indivior generic drug launch pending U.S. ruling

Sept 12 (Reuters) - Teva Pharmaceuticals has agreed to hold off launching its knock-off version of Indivior Plc’s blockbuster opioid addiction drug until the resolution of a U.S. Court case on another generic rival, Indivior said on Wednesday.

The pair’s Indian rival Dr.Reddy’s Laboratories is currently locked in a legal battle in the United States to re-launch a cheaper version of the UK drugmaker’s Suboxone Film.

Indivior also reiterated its full-year net revenues guidance of $25 million to $50 million from its new opioid addiction drug Sublocade, on which the company has pinned its hopes after the legal battles. (Reporting by Arathy S Nair in Bengaluru; editing by Patrick Graham)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below